Norwegian biotech to enact layoffs; Unity halves its public offering
Norwegian drug developer PCI Biotech said it couldn’t secure the funds to bankroll a Phase II cancer trial.
The Oslo biotech put out word Thursday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
